

Transtema Q2'2021 Review - Expect M&A Going Forward

Redeye remains positive to Transtema following a solid Q2 report, conforming the successful transformation to a profitable company. The new financial targets suggest we shall expect M&A going forward, which, if successful, would add a growth dimension to the case. We raise our forecasts and Base case.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Transtema Q2'2021 Review - Expect M&A Going Forward